Lyngbyastatin 2-A Potential Drug For Brain, Gastric, Pros-tate And Ovarian Cancer

Abstract

Cancer is a group of disease characterized by uncontrolled cell divisions leading to abnormal growth of the tissue.  Multidisciplinary scientific investigations are making best efforts to combat this disease, but the perfect cure is yet to be achieved. The side effects of the available drugs make the need for the necessity of new improved drugs. Cyanobacterial resource offers a great scope for discovery of new drugs for cancer. Cyanobacterial novel bioactive compounds with unique biological activities may be useful in finding the potential drugs with greater efficacy, specificity for the treatment of human diseases. Molecular docking is a key tool in structural molecular biology and computer-assisted drug design. Nowadays, molecular docking approaches are routinely used in modern drug design to understand drug–receptor interaction. Computational techniques can strongly support and help the design of novel, more potent inhibitors by revealing the mechanism of drug-receptor interaction. The aim of the present study was to predict the anticancer drug from the members of the cyanobacteria. In silico molecular docking was carried out between the cyanobacterial bioactive compounds, and four different types of cancer causing receptors. The highest energy value was produced by the Lyngbyastatin-2 with various cancer receptor molecules. From the above results, it is concluded that Lyngbyastatin-2, an ideal cyanobacterial drug can be employed as an alternative drug for treating four different cancers without any side effects.